FeesSafety
Pluang+

Stryker shares plunge 8.8% after CFO reveals ongoing manufacturing issues, wiping $10B off market value.

Market News
30 Oct 2026, 20:39 WIB
PRNewsWire
View Source
Bearish
Stryker shares plunge 8.8% after CFO reveals ongoing manufacturing issues, wiping $10B off market value.

Stryker Corporation's shares dropped 8.8% after the CFO disclosed that a manufacturing problem in its Peripheral Vascular unit, initially thought resolved, is still ongoing and expected to continue into the fourth quarter. This revelation wiped out over $10 billion of the company's market capitalization and triggered an investigation by Hagens Berman into whether Stryker adequately disclosed the issue to investors. The investigation focuses on the transparency of Stryker's communications regarding supply disruptions following its acquisition of Inari Medical. Investors who suffered losses or have relevant information are encouraged to contact the law firm for potential legal action.

Stryker Corporation's shares are trading at USD 295.35 on Pluang as of Oct 31, 2026 00:51 WIB, down 5.14% in one day. This price is closer to its 52-week low of USD 269.75 than its 52-week high of USD 387.46, indicating a significant pullback. Despite the decline, Pluang users show strong buying interest with 100% buy orders and no sell orders recorded.

More News (SYK)

Stryker shares plunge 10% after sales guidance cut, new CEO faces tough 2027 start.

Stryker shares plunge 10% after sales guidance cut, new CEO faces tough 2027 start.

Stryker's shares dropped 10% following a guidance cut that impacted sales more than earnings, with adjusted EPS slightly below expectations and revenue missing estimates. Challenges include slow growth in hips and knees markets, supply disruptions, a...

Company Fundamentals
Bearish
11 hours ago
Stryker Q3 sales rise 7.7%, adjusted EPS up 10.3%, but reported EPS falls 11.7%.

Stryker Q3 sales rise 7.7%, adjusted EPS up 10.3%, but reported EPS falls 11.7%.

Stryker reported a 7.7% increase in net sales to $6.5 billion for Q3 2026, driven by organic growth in MedSurg, Neurotechnology, and Orthopaedics. Adjusted earnings per share rose 10.3% to $3.52, reflecting strong operational performance, while repor...

Company Fundamentals
Bullish
1 day ago
Stryker posts 6.1% revenue growth in H1 2026, expects 8.3-9.3% organic growth for full year

Stryker posts 6.1% revenue growth in H1 2026, expects 8.3-9.3% organic growth for full year

Stryker Corporation, a global leader in medical technologies, reported a 6.1% increase in revenue and EBITDA of $3.45 billion for the first half of 2026. Management forecasts organic revenue growth between 8.3% and 9.3% for the full year, with adjust...

Company Fundamentals
Neutral
4 days ago
Stryker completes acquisition of ZuriMED, adding FiberLocker rotator cuff tech to its shoulder care portfolio

Stryker completes acquisition of ZuriMED, adding FiberLocker rotator cuff tech to its shoulder care portfolio

Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...

Company Fundamentals
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App